Evaluating Selected Constituents in the Exhaled Breath Samples
NCT ID: NCT04143256
Last Updated: 2020-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
135 participants
INTERVENTIONAL
2019-10-03
2019-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS
NCT04107779
Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers
NCT03463837
Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers
NCT04088175
Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems
NCT04123041
United States Pre-Market Tobacco Application Pharmacokinetics
NCT03719391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will be screened for participation in the trial up to 28 days before Day 1. Along with screening procedures, all subjects will receive training on EBS collection procedures. All subjects will be further trained on the CPS using a training video and site instructions. Trained subjects will have the opportunity to try the JUUL NSPS.
Eligible subjects will be scheduled for a Day 1 clinic visit. Within 24 to 48 hours prior to Check-in, the clinic staff will provide a courtesy phone call to subjects to remind them to abstain from the use of alcohol, any nicotine-containing products and mint/mentholated products for at least 12 hours prior and xanthines/caffeine for at least 24 hours prior to screening and Day 1.
Following completion of the check-in events, including re-instruction on the EBS sample collection technique and CPS instructions, subjects will participate in the exhaled breath collection test sessions.
Groups I - IV will complete two periods of baseline and test sample collections with a 3-hour break in between each period. Each period will consist of two baseline samples (the first for analysis of nicotine, propylene glycol and glycerin and the second for analysis of acetaldehyde, acrolein, benzoic acid, formaldehyde, and menthol), followed by product use, and then two test samples (similar to baseline). Exhaled CO will be measured before the first baseline sample, after the second baseline sample, before the first test sample and after the second test sample. Pods used during the test sessions will be weighed before and after use.
Groups V and VI will complete only one period of baseline and test sample collections, consisting of two baseline sample collections and two test sample collections similar to that noted above.
A follow-up phone call with subjects will be made the day after Check-out (or early withdrawal). Provided there are no adverse events which require further attention, the subject's participation in the trial will be complete.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
JUUL ENDS 5% Virginia Tobacco
JUUL ENDS Virginia Tobacco 5% nicotine strength
JUUL 3% Virginia Tobacco ENDS
JUUL ENDS Virginia Tobacco 3% nicotine strength
Group II
Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
JUUL 5% Mint ENDS
JUUL ENDS Mint 5% nicotine strength
JUUL 3% Mint ENDS
JUUL ENDS Mint 3% nicotine strength
Group III
Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
JUUL 5% Menthol ENDS
JUUL ENDS Menthol 5% nicotine strength
JUUL 3% Menthol ENDS
JUUL ENDS Menthol 3% nicotine strength
Group IV
Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
JUUL 5% Mango ENDS
JUUL ENDS Mango 5% nicotine strength
JUUL 3% Mango ENDS
JUUL ENDS Mango 3% nicotine strength
Group V
Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
US Cigarette, Non-menthol - Marlboro Gold King Size
US Cigarette, Non-menthol - Marlboro Gold King Size
Group VI
Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
US Cigarette, Menthol - Newport King Size
US Cigarette, Menthol - Newport King Size
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JUUL ENDS 5% Virginia Tobacco
JUUL ENDS Virginia Tobacco 5% nicotine strength
JUUL 3% Virginia Tobacco ENDS
JUUL ENDS Virginia Tobacco 3% nicotine strength
JUUL 5% Mint ENDS
JUUL ENDS Mint 5% nicotine strength
JUUL 3% Mint ENDS
JUUL ENDS Mint 3% nicotine strength
JUUL 5% Menthol ENDS
JUUL ENDS Menthol 5% nicotine strength
JUUL 3% Menthol ENDS
JUUL ENDS Menthol 3% nicotine strength
JUUL 5% Mango ENDS
JUUL ENDS Mango 5% nicotine strength
JUUL 3% Mango ENDS
JUUL ENDS Mango 3% nicotine strength
US Cigarette, Non-menthol - Marlboro Gold King Size
US Cigarette, Non-menthol - Marlboro Gold King Size
US Cigarette, Menthol - Newport King Size
US Cigarette, Menthol - Newport King Size
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be informed of the nature of the study, agree to and are able to read, review, and sign the informed consent document prior to any study procedures. The informed consent document will only be available in English. Therefore, the volunteer must have the ability to read and communicate in English in order to participate in the study.
3. Complete the screening process up to 28 days prior to Day 1.
4. Satisfy the user definitions of either cigarette user or ENDS/closed system user.
5. Agree to abide by the study restrictions.
6. Agree to abstain from use of alcohol 12 hours before the start of Day 1 for Groups I through VI.
7. Agree to abstain from use of any nicotine products 12 hours before the start of study day 1 for Groups I through VI.
8. Agree to not consume any mint or menthol flavor products (e.g., chewing gum, mouth wash, toothpaste, etc.) 12 hours before the start of testing for Groups I through VI.
9. Have a positive urine cotinine result at screening of \>200 ng/ml.
10. A female subject of childbearing potential must have been using one (1) of the following forms of contraception and agree to continue using it through completion of the trial:
* hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection) consistently for at least 3 months prior to Day 1;
* double barrier method (e.g., condom with spermicide, diaphragm with spermicide) at screening.
* intrauterine device for at least 3 months prior to Day 1;
* a partner who has been vasectomized for at least 6 months prior to Day 1;
* abstinence beginning at least 6 months prior to screening.
11. A female subject of non childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Day 1:
* hysteroscopic sterilization;
* bilateral tubal ligation or bilateral salpingectomy;
* hysterectomy;
* bilateral oophorectomy;
* Or be postmenopausal with amenorrhea for at least 1 year prior to Day 1.
12. Be judged by the Investigator to be in good general health as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments and by general observations. Any abnormalities or deviations outside the normal ranges for any clinical testing (e.g. vital signs) can be repeated at the discretion of the Investigator and judged to be not clinically significant for study participation.
Exclusion Criteria
2. Report at screening using both ENDS and conventional cigarettes (menthol or non-menthol) (dual users), or use of other inhaled products (such as, but not limited to cannabis) in the past 3 months.
3. For ENDS users, be unable to perform CPS or incapable of drawing down the pod weight by 20-60mg after 3 attempts at screening.
4. If female, be pregnant, have a positive urine pregnancy test at screening, be lactating, breast feeding, or intend to become pregnant during the time period from screening through the end of the study.
5. Have any clinically significant results from physical examinations and vital signs assessments, as judged by the Investigator.
6. Have a systolic blood pressure \< 90 mmHg or \> 150 mmHg, diastolic blood pressure \< 40 mmHg or \> 95 mmHg, or heart rate \< 40 bpm or \> 99 bpm at screening.
7. Report a clinically significant illness during the 30 days prior to enrollment, as determined by the Investigator.
8. Report a history of drug or alcohol addiction or abuse within the past 1 year.
9. Have a positive screen for alcohol or drugs of abuse at screening or at check-in on Day 1.
10. Have a body mass index (BMI) greater than 40 kg/m2 or less than 18 kg/m2 at screening.
11. Have used prescription anti-diabetic medication and/or insulin therapy within 12 months of screening.
12. Have taken medication for depression, asthma, or chronic obstructive pulmonary disease within 6 months of screening.
13. Have used prescription or over-the-counter bronchodilator medication (e.g., inhaled or oral β-agonists) within 6 months of screening.
14. Be breast-feeding or pregnant female subjects (confirmed by a positive pregnancy test). Female subjects, who are considered women of child bearing potential (WOCBP) and sexually active, must be willing and able to use an acceptable method of contraception from screening through the end of the study.
15. Have experienced an allergic reaction following previous e-cigarette use or with exposure to any primary components of the e-liquids (nicotine, flavor, benzoic acid, propylene glycol, and/or glycerol.
16. Be or have a first-degree relative (i.e. parent, sibling or child) who is a current employee of CRO, Sponsor, or site.
17. In the opinion of an Investigator, be deemed not eligible to participate in this study.
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juul Labs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Frontage Clinical Services
Secaucus, New Jersey, United States
Rose Research Center
Charlotte, North Carolina, United States
Rose Research Center
Raleigh, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oldham MJ, Bailey PC, Castro N, Lang Q, Salehi A, Rostami AA. Prediction of potential passive exposure from commercial electronic nicotine delivery systems using exhaled breath analysis and computational fluid dynamic techniques. J Breath Res. 2021 Oct 5;15(4). doi: 10.1088/1752-7163/ac2884.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROT-00109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.